We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+55.71%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.57B
AUM Growth
+$222M
Cap. Flow
-$306M
Cap. Flow %
-19.56%
Top 10 Hldgs %
71.87%
Holding
41
New
6
Increased
4
Reduced
24
Closed
4

Top Buys

Rank Stock Value
1
CTMX icon
CytomX Therapeutics
CTMX
+$20.2M
2
KALV
KalVista Pharmaceuticals
KALV
+$16M
3
BHVN icon
Biohaven
BHVN
+$8.71M
4
CGEM icon
Cullinan Oncology
CGEM
+$7.32M
5
ALEC icon
Alector
ALEC
+$3.55M

Top Sells

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$81.1M
2
COGT icon
Cogent Biosciences
COGT
+$48.4M
3
CGON icon
CG Oncology
CGON
+$43.8M
4
ENGN icon
enGene Therapeutics
ENGN
+$28.1M
5
MBX
MBX Biosciences
MBX
+$25.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.79B
$219M 13.99%
6,165,223
-1,720,949
-22% -$48.4M
VERA icon
2
Vera Therapeutics
VERA
$2.54B
$174M 11.11%
3,433,051
-594,749
-15% -$21.1M
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.84B
$169M 10.81%
8,050,959
-469,041
-6% -$8.18M
CLDX icon
4
Celldex Therapeutics
CLDX
$2.77B
$161M 10.31%
5,943,180
-157,549
-3% -$4.15M
PCVX icon
5
Vaxcyte
PCVX
$7.89B
$135M 8.61%
2,922,335
-149,253
-5% -$6.68M
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.37B
$73.1M 4.67%
9,366,526
-23,744
-0.3% -$172K
BEAM icon
7
Beam Therapeutics
BEAM
$2.58B
$67.6M 4.32%
2,440,214
-77,433
-3% -$1.98M
VRDN icon
8
Viridian Therapeutics
VRDN
$2.13B
$45.8M 2.92%
1,470,541
-2,957,386
-67% -$81.1M
TYRA icon
9
Tyra Biosciences
TYRA
$1.82B
$41.1M 2.63%
1,564,492
-765,506
-33% -$14.1M
CGON icon
10
CG Oncology
CGON
$6.11B
$39.3M 2.51%
945,830
-1,059,375
-53% -$43.8M
CTMX icon
11
CytomX Therapeutics
CTMX
$705M
$38.2M 2.44%
8,966,077
+5,319,574
+146% +$20.2M
NRIX icon
12
Nurix Therapeutics
NRIX
$2.43B
$37.4M 2.39%
1,970,357
-198,248
-9% -$2.85M
WVE icon
13
Wave Life Sciences
WVE
$1.12B
$36.9M 2.36%
2,169,105
-2,390,948
-52% -$24.3M
CGEM icon
14
Cullinan Oncology
CGEM
$1.05B
$32.2M 2.06%
3,114,132
+811,960
+35% +$7.32M
IMCR icon
15
Immunocore
IMCR
$1.78B
$29.7M 1.9%
856,462
-152,805
-15% -$5.39M
MBX
16
MBX Biosciences
MBX
$2.95B
$29.5M 1.88%
934,799
-1,065,201
-53% -$25.8M
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$29.2M 1.87%
1,810,954
+1,204,783
+199% +$16M
BEAM icon
18
CALL
Beam Therapeutics
BEAM
$2.58B
$26M 1.66%
+937,000
New +$23.9M
APLS
19
DELISTED
Apellis Pharmaceuticals
APLS
$22.8M 1.46%
908,607
+100,000
+12% +$2.35M
DVAX
20
DELISTED
Dynavax Technologies
DVAX
$21.2M 1.35%
1,375,632
-769,687
-36% -$8.48M
BNR
21
Burning Rock Biotech
BNR
$94.4M
$20M 1.28%
994,883
– –
TVTX icon
22
Travere Therapeutics
TVTX
$5.33B
$19.8M 1.26%
517,884
-431,843
-45% -$14M
PHVS icon
23
Pharvaris
PHVS
$2.39B
$17.8M 1.14%
640,395
-34,605
-5% -$833K
ENGN icon
24
enGene Therapeutics
ENGN
$122M
$13.5M 0.86%
1,492,898
-3,501,192
-70% -$28.1M
RLAY icon
25
Relay Therapeutics
RLAY
$4.02B
$12M 0.77%
1,424,259
-1,462,755
-51% -$10.4M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Kynam Capital Management held 41 positions worth $1.57B, up 17% from $1.34B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Kynam Capital Management withdrew a net $306M in Q4 2025, closing 4 positions and reducing 24 holdings. Its most notable exit was United Therapeutics, an estimated $20M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Kynam Capital Management opened a new position in Biohaven worth $7.94M.

  • Kynam Capital Management's largest Q4 2025 buy was Biohaven: 702,884 shares worth $7.94M.
  • Kynam Capital Management added most to CytomX Therapeutics in Q4 2025, an estimated $20.2M increase.
  • Kynam Capital Management's biggest Q4 2025 reduction was Viridian Therapeutics, cutting an estimated $81.1M.
  • Kynam Capital Management fully exited United Therapeutics in Q4 2025, selling an estimated $20M.
  • Kynam Capital Management's ten largest holdings make up 72% of its $1.57B portfolio in Q4 2025.
  • Kynam Capital Management opened 6 new positions and closed 4 in Q4 2025.
  • Kynam Capital Management's portfolio value rose 17% quarter-over-quarter to $1.57B.

Based on Kynam Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.